PortfoliosLab logoPortfoliosLab logo
SURI vs. IDNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

SURI vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Simplify Propel Opportunities ETF (SURI) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SURI achieves a 6.10% return, which is significantly lower than IDNA's 10.31% return.


SURI

1D
-1.15%
1M
-2.84%
YTD
6.10%
6M
3.98%
1Y
32.89%
3Y*
6.93%
5Y*
10Y*

IDNA

1D
0.73%
1M
-2.56%
YTD
10.31%
6M
8.52%
1Y
40.87%
3Y*
6.74%
5Y*
-8.42%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

SURI vs. IDNA - Yearly Performance Comparison


Correlation

The correlation between SURI and IDNA is 0.50, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.50

Correlation (3Y)
Calculated over the trailing 3-year period

0.62

Correlation (All Time)
Calculated using the full available price history since Feb 9, 2023

0.62

The correlation between SURI and IDNA shifts across timeframes, from 0.50 (1 year) to 0.62 (all time), reflecting how their relationship changes across market environments.

SURI vs. IDNA - Sectors Allocation Comparison


Sectors
SURI
IDNA

Healthcare

56.4%
97.8%

Energy

43.6%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Financial Services

-

-

Industrials

-

0.4%

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

SURI
56.4%
IDNA
97.8%

Energy

SURI
43.6%
IDNA

-

Basic Materials

SURI

-

IDNA

-

Communication Services

SURI

-

IDNA

-

Consumer Cyclical

SURI

-

IDNA

-

Consumer Defensive

SURI

-

IDNA

-

Financial Services

SURI

-

IDNA

-

Industrials

SURI

-

IDNA
0.4%

Real Estate

SURI

-

IDNA

-

Technology

SURI

-

IDNA

-

Utilities

SURI

-

IDNA

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SURI vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SURI
SURI Risk / Return Rank: 4545
Overall Rank
SURI Sharpe Ratio Rank: 4141
Sharpe Ratio Rank
SURI Sortino Ratio Rank: 4242
Sortino Ratio Rank
SURI Omega Ratio Rank: 3939
Omega Ratio Rank
SURI Calmar Ratio Rank: 5757
Calmar Ratio Rank
SURI Martin Ratio Rank: 4848
Martin Ratio Rank

IDNA
IDNA Risk / Return Rank: 5555
Overall Rank
IDNA Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
IDNA Sortino Ratio Rank: 4949
Sortino Ratio Rank
IDNA Omega Ratio Rank: 4242
Omega Ratio Rank
IDNA Calmar Ratio Rank: 7676
Calmar Ratio Rank
IDNA Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SURI vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Simplify Propel Opportunities ETF (SURI) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SURIIDNADifference
Sharpe ratioReturn per unit of total volatility

-0.22

Sortino ratioReturn per unit of downside risk

-0.33

Omega ratioGain probability vs. loss probability

1.26

1.27

-0.02

Calmar ratioReturn relative to maximum drawdown

2.81

3.85

-1.04

Martin ratioReturn relative to average drawdown

7.91

10.98

-3.07

SURI vs. IDNA - Sharpe Ratio Comparison

The current SURI Sharpe Ratio is 1.46, which is comparable to the IDNA Sharpe Ratio of 1.68. The chart below compares the historical Sharpe Ratios of SURI and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SURIIDNADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.46

1.68

-0.22

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.30

Sharpe Ratio (All Time)

Calculated using the full available price history

0.15

0.10

+0.05

Drawdowns

SURI vs. IDNA - Drawdown Comparison

The maximum SURI drawdown since its inception was -47.76%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for SURI and IDNA.


Loading charts...

Drawdown Indicators


SURIIDNADifference

Max Drawdown

Largest peak-to-trough decline

-47.76%

-68.26%

+20.50%

Max Drawdown (1Y)

Largest decline over 1 year

-11.78%

-10.66%

-1.12%

Max Drawdown (3Y)

Largest decline over 3 years

-47.76%

-29.73%

-18.03%

Max Drawdown (5Y)

Largest decline over 5 years

-68.26%

Current Drawdown

Current decline from peak

-17.46%

-45.61%

+28.15%

Average Drawdown

Average peak-to-trough decline

-17.37%

-36.24%

+18.87%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.17%

3.73%

+0.44%

Volatility

SURI vs. IDNA - Volatility Comparison

The current volatility for Simplify Propel Opportunities ETF (SURI) is 5.89%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 7.18%. This indicates that SURI experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SURIIDNADifference

Volatility (1M)

Calculated over the trailing 1-month period

5.89%

7.18%

-1.29%

Volatility (6M)

Calculated over the trailing 6-month period

14.29%

17.98%

-3.69%

Volatility (1Y)

Calculated over the trailing 1-year period

22.79%

24.48%

-1.69%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

28.27%

28.42%

-0.15%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

28.27%

29.53%

-1.26%

SURI vs. IDNA - Expense Ratio Comparison

SURI has a 2.51% expense ratio, which is higher than IDNA's 0.47% expense ratio.


Dividends

SURI vs. IDNA - Dividend Comparison

SURI's dividend yield for the trailing twelve months is around 16.04%, more than IDNA's 1.07% yield.


PositionTTM2025202420232022202120202019
IDNA
iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund
1.07%1.18%0.98%1.04%0.54%0.70%0.26%0.80%
SURI
Simplify Propel Opportunities ETF
16.04%16.31%21.41%14.71%0.00%0.00%0.00%0.00%

Frequently Asked Questions


SURI and IDNA have a correlation of 0.50, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

IDNA has higher volatility (7.18%) compared to SURI (5.89%). In terms of maximum drawdown, SURI dropped -47.76% vs IDNA's -68.26%.

On 3-year performance, SURI leads with 6.93% vs 6.74% for IDNA. On fees, IDNA is cheaper at 0.47% per year. On volatility, SURI has been the lower-risk option at 5.89%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 3-year period, SURI has performed better with a 6.93% return vs 6.74%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IDNA is cheaper with a 0.47% expense ratio, compared with 2.51% for SURI.

SURI has the higher dividend yield at 16.04%, compared with 1.07% for IDNA.

They also come from different issuers: Simplify and iShares. Their fees differ too: 2.51% for SURI and 0.47% for IDNA.

IDNA currently has the higher Sharpe Ratio (1.68 vs 1.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SURI and IDNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer